Canadian nod for Otsuka/Lundbeck's Abilify Maintena
This article was originally published in Scrip
Executive Summary
Canada has become the latest market to approve Abilify Maintena, the once-monthly intramuscular injection formulation of Otsuka Pharmaceutical's atypical antipsychotic aripiprazole.